List of Studies ( Metabolite:Ile-Lys-Pro)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST004291 | AN007135 | Metabolomics analysis of Plasmodium falciparum asexual-stage parasites treated with plasmepsin V peptidomimetics - 16 hour treatment | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST004290 | AN007133 | Metabolomics characterisation of Plasmodium falciparum response to plasmepsin V peptidomimetic inhibitors - 5 hour treatment | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST004194 | AN006966 | PfK13-associated artemisinin resistance slows drug activation and enhances antioxidant defence, which can be overcome with sulforaphane | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003778 | AN006205 | Human to mouse microbiota transfer model demonstrates disease-modifying effects of the short-chain fatty acid biotherapy modified microbiota | Feces | Mouse | Diabetes | University of Queensland | LC-MS |
| ST003565 | AN005857 | Metaboloomics analysis of the antimalarial compound WEHI-1888504 (aka compound 59) in Plasmodium falciparum (3D7) infected red blood cells | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003521 | AN005782 | Metabolic Profiling Unveils Enhanced Antibacterial Synergy of Polymyxin B and Teixobactin against Multi-Drug Resistant Acinetobacter baumannii | Bacterial cells | Acinetobacter baumannii | Bacterial infection | Monash University | LC-MS |
| ST003179 | AN005221 | Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4 | Plasmodium cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003144 | AN005159 | On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003036 | AN004977 | Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 2 | Bacterial cells | Pseudomonas aeruginosa | Bacterial infection | Monash Institute of Pharmaceutical Sciences | LC-MS |
| ST003024 | AN004958 | Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 1 | Bacterial cells | Pseudomonas aeruginosa | Monash Institute of Pharmaceutical Sciences | LC-MS | |
| ST002926 | AN004798 | Multi-“omics” analysis reveals the orphan P. falciparum protein kinase PfPK8 regulates multi-gene family expression | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002792 | AN004542 | Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002698 | AN004372 | Systemic host inflammation induces stage-specific transcriptomic modification and slower maturation in malaria parasites | Infected Red Blood Cells | Plasmodium berghei | Malaria | Peter Doherty Institute for Infection and Immunity | LC-MS |
| ST002412 | AN003931 | Metabolic effects of the protein kinase R | Macrophages | Mouse | Hudson Institute of Medical Research | LC-MS | |
| ST002309 | AN003771 | Targeting malaria parasites with novel derivatives of azithromycin | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002106 | AN003444 | Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 1) | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002104 | AN003439 | Chemoresistant Cancer Cell Lines are Characterized by Migratory, Amino Acid Metabolism, Protein Catabolism and IFN1 Signalling Perturbations | Cultured cells | Human | Cancer | Future Industries Institute | LC-MS |
| ST002010 | AN003276 | Chemoresistant Ovarian Cancer Global Metabolomics | Cultured cells | Human | Cancer | University of South Australia | LC-MS |
| ST001549 | AN002580 | β-Adrenergic regulation of metabolism in macrophages (part-III) | Macrophages | Human | Monash University | LC-MS | |
| ST001547 | AN002576 | β-Adrenergic regulation of metabolism in macrophages | Macrophages | Human | Monash University | LC-MS | |
| ST001315 | AN002189 | Retargeting azithromycin-like compounds as antimalarials with dual modality | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001304 | AN002172 | Multi-omics analysis delineates the distinct functions of sub-cellular acetyl-CoA pools in Toxoplasma gondii | Fibroblast cells | Toxoplasma gondii | Parasitic infection | Monash University | LC-MS |
| ST001201 | AN001998 | Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | LC-MS |
| ST001201 | AN001998 | Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001175 | AN001950 | Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparum | Plasmodium cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001033 | AN001694 | Determination of mode of action of anti-malalrial drugs using untargeted metabolomics | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST000546 | AN000832 | Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant Plasmodium | Cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST000414 | AN000655 | Metabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of action | Cells | Plasmodium falciparum | Malaria | Monash Institute of Pharmaceutical Sciences | LC-MS |
